The wholesale acquisition cost of one-time Luxturna treatment for confirmed biallelic RPE65 mutation-associated retinal dystrophy is $425,000 per eye, Spark Therapeutics confirmed in an email to Healio.com/OSN.
Spark Therapeutics also announced three new payer programs: an outcomes-based rebate arrangement with long-term durability measure, a contracting model and a proposal to CMS under which payments for Luxturna (voretigene neparvovec-rzyl) would be made over time, according to a company release.
Luxturna will cost $850,000 total to treat both eyes. Biallelic RPE65 mutation-associated
Uncategorized